KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure

Last updated: June 2, 2026
Sponsor: SterileCare Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Bulimia

Treatment

KiteLock 4% Sterile Catheter Lock Solution

Heparin Lock Solution

Clinical Study ID

NCT05879835
CT23-001-SC001
  • Ages 4-18
  • All Genders

Study Summary

A multi-site, randomized, 2-arm open-label trial to determine if 4% Tetrasodium (EDTA) catheter lock solution is more effective than heparin lock (standard of care) in preventing central venous catheter occlusions in children with intestinal failure (IF) on total parenteral nutrition (TPN).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients managed by the intestinal rehabilitation program at one of theparticipating centers.

  2. Diagnosis of intestinal failure defined as need for PN support for >60 days inprevious 74 days for primary intestinal disease (short bowel syndrome, primarymotility disorder, mucosal enteropathy).

  3. Expectation of the treating physician that the patient will require PN for at least 6 months following enrollment.

  4. Age less than 18 years at diagnosis but greater than 4 weeks chronological age or 40weeks estimated gestational age, whichever is greater.

  5. Stable TPN cycling (4 hours off TPN minimum per day) enabling home TPN management

  6. Presence of a tunneled central venous catheter (CVC), port-a-catheter, orperipherally inserted central catheter (PICC).

  7. Clinical stability for at least 4 weeks and no acute medical comorbidities.

  8. A minimum dwell time of 4 consecutive hours daily.

  9. Care provider willing to provide informed consent to participate in the trial andwilling to comply with randomization and study protocol.

Exclusion

Exclusion Criteria:

  1. A temporary CVC (jugular or femoral) or peripheral catheter.

  2. Patients receiving long-term PN, but not due to a primary intestinal disorder (i.e.,oncology patients or premature neonates on PN due to intestinal immaturity).

  3. Known hypersensitivity, allergy, or reaction to EDTA.

  4. Pregnancy or nursing mother.

  5. Participation in another investigational device or drug trial within 30 days priorto enrollment (unless approved by the principal investigators of the trial).

  6. Severe coagulopathy (platelets <50,000, or INR > 1.5).

  7. Diagnosis of immunodeficiency disorder.

  8. Unstable medical condition requiring hospital admission

  9. Received antibiotic therapy for CLABSI within last 14 days.

Study Design

Total Participants: 124
Treatment Group(s): 2
Primary Treatment: KiteLock 4% Sterile Catheter Lock Solution
Phase:
Study Start date:
June 21, 2024
Estimated Completion Date:
June 30, 2027

Study Description

A total of 124 (62 per arm) will be enrolled into the study. Screening and informed consent (and assent if applicable) will be obtained prior to study procedures. The baseline assessment will be completed at recruitment to the study. Once the baseline assessment is complete and eligible subjects are randomized, the study drug will be dispensed per protocol. The study follow-up period will be 52 weeks. Four follow-up clinical in-person visits will occur at 2,12, 28, 40 and 52 weeks. Visits will be conducted by physicians or nurse practitioners. The study visits will assess general status, study bloodwork, adverse events, catheter patency, alteplase use, infection assessment, catheter integrity, and provide investigational product. Telephone follow up will occur on day-3 of intervention, and once per 4 weeks, as well as in the event of outpatient care/hospital admission, or safety event. Subject daily diaries will be utilized for detailed monitoring. Diary recordings will include adverse events, including occlusive events, and any subject specific details (e.g. dwell times, heparin flushing vs. aspiration) or issues in the delivery of the study locking solutions.

Connect with a study center

  • Boston Children's Hospital

    Boston, Massachusetts 02115
    United States

    Active - Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska 68198
    United States

    Site Not Available

  • Nyph/Cumc

    New York, New York 10032
    United States

    Active - Recruiting

  • Duke University Medical Center

    Durham, North Carolina 27710
    United States

    Active - Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio 45229
    United States

    Active - Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio 43205
    United States

    Active - Recruiting

  • Cook Children's Health Care System

    Fort Worth, Texas 76104
    United States

    Active - Recruiting

  • Seattle Children's Hospital

    Seattle, Washington 98105
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.